Free Trial

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $11,701.66 in Stock

BioLife Solutions logo with Medical background

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 521 shares of the firm's stock in a transaction on Wednesday, May 28th. The shares were sold at an average price of $22.46, for a total value of $11,701.66. Following the sale, the executive vice president now directly owns 308,486 shares of the company's stock, valued at $6,928,595.56. This represents a 0.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

BioLife Solutions Trading Up 3.3%

Shares of BLFS stock traded up $0.69 on Tuesday, hitting $21.38. 482,928 shares of the company's stock traded hands, compared to its average volume of 392,342. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -20.17 and a beta of 2.01. The company's fifty day simple moving average is $22.67 and its 200 day simple moving average is $25.06. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a one year low of $18.70 and a one year high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.07. The firm had revenue of $23.94 million during the quarter, compared to analysts' expectations of $22.22 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. Equities analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on BLFS shares. HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of BioLife Solutions in a research report on Tuesday, May 13th. Wall Street Zen downgraded BioLife Solutions from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $31.17.

Check Out Our Latest Report on BLFS

Hedge Funds Weigh In On BioLife Solutions

A number of hedge funds have recently bought and sold shares of the business. Stephens Investment Management Group LLC increased its stake in shares of BioLife Solutions by 16.7% in the 4th quarter. Stephens Investment Management Group LLC now owns 495,970 shares of the medical equipment provider's stock worth $12,875,000 after purchasing an additional 70,875 shares in the last quarter. Principal Financial Group Inc. grew its holdings in BioLife Solutions by 28.1% during the fourth quarter. Principal Financial Group Inc. now owns 244,247 shares of the medical equipment provider's stock valued at $6,341,000 after purchasing an additional 53,532 shares during the period. D.A. Davidson & CO. increased its position in BioLife Solutions by 1.3% in the fourth quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider's stock worth $1,069,000 after buying an additional 519 shares in the last quarter. Peregrine Capital Management LLC raised its stake in shares of BioLife Solutions by 18.1% in the fourth quarter. Peregrine Capital Management LLC now owns 352,205 shares of the medical equipment provider's stock worth $9,143,000 after buying an additional 54,100 shares during the period. Finally, New York State Common Retirement Fund lifted its position in shares of BioLife Solutions by 4.3% during the 4th quarter. New York State Common Retirement Fund now owns 260,315 shares of the medical equipment provider's stock valued at $6,758,000 after buying an additional 10,836 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company's stock.

BioLife Solutions Company Profile

(Get Free Report)

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Recommended Stories

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Should You Invest $1,000 in BioLife Solutions Right Now?

Before you consider BioLife Solutions, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.

While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA
This Unique Robotaxi Play Could Deliver 10X Returns

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines